CBD for Knee Osteoarthritis - Trial NCT06414473
Access comprehensive clinical trial information for NCT06414473 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by University of Florida and is currently Not yet recruiting. The study focuses on Osteoarthritis, Knee. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Florida
Timeline & Enrollment
Phase 1/2
Jun 01, 2024
Dec 31, 2026
Primary Outcome
Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE),Theoretical Framework of Acceptability Questionnaire (TFAQ),Self-report Ratings of Knee Pain,Physical Activity,Western Ontario and McMaster Universities Arthritis Index (WOMAC)
Summary
Osteoarthritis is a disease that affects millions of Americans and is the leading cause of
 persistent pain and physical disability in the older adult population. Many physically active
 Americans have reported pain-relieving effects of cannabidiol (CBD) that can reduce or
 eliminate use of nonsteroidal anti-inflammatory drugs (NSAIDs) for activity-related pain with
 minimal to no side effects. Long-term use of over-the-counter medications, including NSAIDs,
 can pose a significant health risk, and therefore clinical research on the safety and
 efficacy of CBD is needed.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06414473
Non-Device Trial